FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Codon topics
Hydrocodone
Nucleic Acid
Acetaminophen
Carboxylic Acid
Benzoic Acid
Genetically
Recombinant
Amino Acid
Nucleotide
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor
Reverse Transcriptase
Antibodies
Base Sequence
Replication

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Codon patents



      
           
This page is updated frequently with new Codon-related patent applications. Subscribe to the Codon RSS feed to automatically get the update: related Codon RSS feeds. RSS updates for this page: Codon RSS RSS


Date/App# patent app List of recent Codon-related patents
07/24/14
20140206871
 Low abuk oxycodone, its salts and methods of making same patent thumbnailnew patent Low abuk oxycodone, its salts and methods of making same
A method of preparing oxycodone includes forming 14-hydroxycodeine by reduction of 14-hydroxycodeinone and rearrangement of the 14-hydroxycodeine to form the oxycodone. During the reduction step, the ketone group of an undesirable contaminant precursor, 8,14-dihydroxy-7,8-dihydrocodeinone, is reduced to a hydroxyl group thus forming a triol.
07/24/14
20140206637
 Inhibition of nonsense mediated mrna decay by drugs that prevent hypusination of eukaryotic initiation factor 5a patent thumbnailnew patent Inhibition of nonsense mediated mrna decay by drugs that prevent hypusination of eukaryotic initiation factor 5a
Provided are methods for treating a nad comprising administering to a patient suffering from a nad an inhibitor of nmd and a nonsense suppressor, whereby degradation of nmd susceptible mrna is decreased and translation termination at a misplaced nonsense codon is blocked.. .
07/24/14
20140206579
 Dna libraries encoding frameworks with synthetic cdr regions patent thumbnailnew patent Dna libraries encoding frameworks with synthetic cdr regions
A synthetic dna library or a member of a synthetic dna library of antibodies or fragments of antibody molecules having heavy chain(s) and lacking light chain(s) is described wherein the cdr within variable domains are synthesized using randomly assembled trinucleotide phosphoramidites (trimer phosphoramidites) to eliminate unwanted cysteine amino acids and/or stop codons.. .
07/24/14
20140206070
 Vector with codon-optimised genes for an arabinose metabolic pathway for arabinose conversion in yeast for ethanol production patent thumbnailnew patent Vector with codon-optimised genes for an arabinose metabolic pathway for arabinose conversion in yeast for ethanol production
The present invention relates to novel expression cassettes and expression vectors, comprising three nucleic acid sequences for araa, arab and arad, each coding for a polypeptide of an l-arabinose metabolic pathway, in particular, a bacterial l-arabinose metabolic pathway. The invention particularly relates to expression cassettes and expression vectors, comprising codon-optimised nucleic acid sequences for araa, arab and arad.
07/17/14
20140199394
 Controlled release hydrocodone patent thumbnailControlled release hydrocodone
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
07/03/14
20140186926
 Baculoviral vectors comprising repeated coding sequences with differential codon biases patent thumbnailBaculoviral vectors comprising repeated coding sequences with differential codon biases
The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors..
07/03/14
20140186382
 Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection patent thumbnailCodon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding hcmv antigens, in which the naturally-occurring coding regions for the hcmv antigens have been modified for improved translation in human or other mammalian cells through codon optimization.
07/03/14
20140186300
 Targeted pre-mrna/mrna modification and gene regulation patent thumbnailTargeted pre-mrna/mrna modification and gene regulation
Methods for affecting mrna expression or translation through the modification of pre-mrna or mrna transcripts are described. In one embodiment of the methods of the present invention, the branch point adenosine of a pre-mrna transcript is 2′-0-methylated to block splicing and subsequent expression of the protein encoded by the transcript.
06/26/14
20140179729
 Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer patent thumbnailOral dosage forms for oxygen-containing active agents and oxyl-containing polymer
The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts.
06/26/14
20140179728
 Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer patent thumbnailOral dosage forms for oxygen-containing active agents and oxyl-containing polymer
The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts.
06/26/14
20140179538
Mutations in pancreatic neoplasms
To help reveal the pathogenesis of these lesions, we purified the dna from intraductal papillary mucinous neoplasm (ipmn) cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. We identified recurrent mutations at codon 201 of gnas.
06/26/14
20140179004
Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
A cell of the present invention contains a nucleic acid construct encoding a wt1 gene product or a fragment of the wt1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the wt1 gene product and (ii) only aug as a functional start codon.
06/19/14
20140171620
Ciliary neurotrophic factor variants
Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in seq id: no 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in seq id: no 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (cntfr), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (il-6r), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in seq id: no 2 having a non-positively charged amino acid residue.. .
06/19/14
20140170217
Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof..
06/12/14
20140162935
Compositions comprising enzyme-cleavable oxycodone prodrug
The embodiments provide compound kc-8, n-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, compound kc-8, that provides controlled release of oxycodone.
06/12/14
20140161879
Treating pain in patients with hepatic impairment
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition comprises a multiparticulate modified release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules as the primary package.
06/05/14
20140154744
Compositions and methods for making selenocysteine containing polypeptides
Non-naturally occurring trnasec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring trnasec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mrna without the requirement of an secis element.
05/29/14
20140147459
Computationally optimized broadly reactive antigens for h1n1 influenza
Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2012.
05/22/14
20140141090
Pharmaceutical composition comprising opioid agonist and sequestered antagonist
This invention pertains to pharmaceutical composition comprising a plurality of multi-layered beads having an oxycodone layer and a sequestering subunit comprising a naltrexone and a blocking agent, in particular pharmaceutical compositions comprising a higher level of naltrexone, and related compositions and methods of use, such as in the prevention of abuse of a therapeutic agent. The compositions of the present invention also have a long tmax for oxycodone release and a flatter release profile of oxycodone over time..
05/08/14
20140127248
Computationally optimized broadly reactive antigens for h1n1 influenza
Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2011.
05/01/14
20140121124
Compositions and methods for the identification of inhibitors of retroviral infection
Methods of identifying inhibitors of retroviral propagation, trna used in the methods, and kits, including the trna, which can be used in the methods, are disclosed. Methods of treating or preventing retroviral infections by administering an effective amount of the inhibitors, and pharmaceutical compositions including the inhibitors, are also disclosed.
05/01/14
20140120061
Abuse resistant melt extruded formulation having reduced alcohol interaction
The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient.
04/24/14
20140112981
Controlled release hydrocodone formulations
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
04/17/14
20140106401
Selection of host cells expressing protein at high levels
Described is a dna molecule comprising an open reading frame sequence encoding a selectable marker polypeptide, wherein the dna molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a gtg or ttg start codon, and wherein the orf sequence that encodes the selectable marker protein has been mutated to replace at least half of its cpg dinucleotides as compared to the native orf sequence that encodes the selectable marker protein. Further provided are such dna molecules wherein the orf sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest.
04/10/14
20140099338
Yeast expressed classical swine fever virus glycoprotein e2 and use thereof
The present invention provides a recombinant yeast system for expressing the glycoprotein e2 of classical swine fever virus (csfv), in which the expression level of ye2 is improved by codon optimization and shortening coding region of e2 gene. The truncated e2 subunits are used as major active ingredient in anti-csfv vaccines and useful diagnostic blocking elisa kits for csfv infection with easy manipulation and low cost..
04/03/14
20140094457
Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay
The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature termination codons, or other conditions that render messenger ribonucleic acid (mrna) susceptible to nonsense mediated rna decay, in a subject.
04/03/14
20140093942
Gene, ars-r anchorage cassette, ars-r expression-anchorage cassette, recombinant plasmid, bacterial transgenic lineage, use of said gene, use of said lineage in environmental bioremediation processes
The present invention relates to the construction and insertion of a dna plasmid vector of broad spectrum for gram-negative bacteria, that carries a gene sequence which, when expressed, enables the anchorage of a chelator protein for arsenic ions on the gram-negative bacteria cellular surface. For that end, the structural sequence of the regulatory arsr gene without stop codon (seq id no 1) was amplified by polymerase chain reaction (pcr) using as a template the chromosome 1 of cupriavidus metallidurans, ch34 lineage and inserted into the pgem-t cloning vector, yielding the pgemt-as plasmid (seq id no 2).
03/27/14
20140087402
Synthetic luciferase gene and protein
A codon optimized and stabilized luciferase gene and a novel recombinant dna characterized by incorporating this new gene coding for a novel luciferase into a vector dna for improved activities in mammalian cells, are disclosed. This new luciferase exhibits long-wavelength light emission, as well as improved thermostability and higher expression levels in mammalian cell systems, compared to native luciferase.
03/27/14
20140086951
Pharmaceutical composition and methods for modulating immune system, preventing, pretreating and/or treating cancers
This invention provides a pharmaceutical composition for modulating immune system comprising at least one polysaccharide extracted from radix astragali, radix codonopsis, ganoderma sinense, or mixtures thereof, and their extraction process. The present invention further relates to a method of modulating immune system by applying said pharmaceutical composition to a subject suffering from cancers, and a method of preventing and/or pretreating and/or treating cancers in the subject, where said method comprises applying said pharmaceutical composition before/during chemotherapy..
03/20/14
20140082760
Non-human animals expressing ph-sensitive immunoglobulin sequences
Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and or in a loop 4 region are also provided.
03/20/14
20140079731
Sin nombre virus full-length m segment-based dna vaccines
The invention contemplates a new synthetic, codon-optimized sin nombre virus (snv) full-length m gene open reading frame (orf) that encodes a unique consensus amino acid sequence. The snv orf was cloned into a plasmid to form the first stable recombinant snv full-length m gene that elicits neutralizing antibodies.
02/20/14
20140051170
Process, vectors and engineered cell lines for enhanced large-scale transfection
Processes, vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially chinese hamster ovary (cho) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional orip sequences in all plasmids, the use of codon-optimized epstein-barr virus nuclear antigen-1 (ebna1) constructs, the use of a fusion protein between a truncated epstein-barr virus nuclear antigen-1c (ebna1c) protein and a herpes simplex virus protein vp16, the use of a 40 kda fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (fgf) and/or the use of protein kinase b to potentiate heterologous gene expression enhancement by valproic acid (vpa).. .
02/13/14
20140045877
Pharmaceutical preparation containing oxycodone and naloxone
The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.. .
02/13/14
20140045876
Process
The present invention provides a process for preparing an oxycodone acid adduct, said process comprising hydrogenating an aqueous solution of 14-hydroxycodeinone and an acid to form a solution of the oxycodone acid adduct, wherein the hydrogenation is carried out at one or more temperatures greater than ambient temperature in the presence of a hydrogenation catalyst and hydrogen gas, wherein the solution of oxycodone acid adduct comprises 6α-oxycodol in an amount ≦about 0.800 area % as determined by hplc.. .
02/13/14
20140045261
Site-specific incorporation of amino acids into molecules
The invention provides certain embodiments relating to methods and compositions for incorporating non-natural amino acids into a polypeptide or protein by utilizing a mutant or modified aminoacyl-trna synthetase to charge the non-natural amino acid to a the corresponding trna. In certain embodiments, the trna is also modified such that the complex forms strict watson-crick base-pairing with a codon that normally forms wobble base-pairing with unmodified trna/aminoacyl-trna synthetase pairs..
02/13/14
20140044782
Controlled release formulations of opioid and nonopioid analgesics
Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic.
02/06/14
20140038286
Codon optimized sodium-iodide symporter gene and its use
The present disclosure provides a polynucleotide which is codon optimized for the efficient expression in a eukaryotic cell, a plasmid and a eukaryotic cell comprising the same. The modification resulted in the efficient expression of nis in eukaryotic cells and the enhancement of the function of nis by glycosylation.
01/30/14
20140031382
Dosage form containing oxycodone and naloxone
The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as tmax, cmax, auct value, mean bowel function score and/or duration of analgesic efficacy.. .
01/30/14
20140030707
Small rna-dependent translational regulatory system in cell or artificial cell model
An object of the present invention is to construct an mrna which specifically responds to a short rna sequence and can activate, repress, and regulate the translation of the desired gene, and to construct an artificial cell model system using a liposome comprising the mrna and a cell-free translational system encapsulated therein. The present invention provides: an mrna comprising a target rna-binding site located immediately 5′ to the ribosome-binding site, and a nucleotide sequence located 5′ to the target rna-binding site, the nucleotide sequence being complementary to the ribosome-binding site; an mrna comprising a small rna-binding site located 3′ to the start codon, and a nucleotide sequence located 3′ to the small rna-binding site, the nucleotide sequence encoding a protein; and a liposome comprising any of these mrnas encapsulated therein..
01/23/14
20140024806
Glycoproteins produced in plants and methods of their use
Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cdnas for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cdnas to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields.
01/16/14
20140018257
Peptide library production method, peptide library, and screening method
Object is to provide a method of constructing a library of peptides having, at a desired position in the random sequence of each peptide, an amino acid having a portion capable of binding to a target. The invention provides a method of producing a library of peptides having, at a designated position in the random sequence of each peptide, a special amino acid having a portion capable of binding to a target, including (i) preparing a library of mrnas having, in the mrna sequence coding for a random amino acid sequence, a base sequence having an altered codon encoding the special amino acid, (ii) preparing an aminoacyl trna with the special amino acid linked to a trna encoded by the altered codon, and (iii) translating the mrnas by using a cell-free translation system containing the aminoacyl trna to obtain a library of peptides having, in the random sequence thereof, a predetermined special amino acid..
01/16/14
20140017259
Immunotherapy against erbb-3 receptor
The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid dna and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the erbb-3 receptor.
01/09/14
20140013456
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
01/09/14
20140011262
Methods for producing secreted polypeptides
The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a nucleic acid construct comprising a first nucleotide sequence encoding a signal peptide operably linked to a second nucleotide sequence encoding the polypeptide, wherein the first nucleotide sequence is foreign to the second nucleotide sequence and the 3′ end of the first nucleotide sequence is immediately upstream of the initiator codon of the second nucleotide sequence. The present invention also relates to the isolated signal peptide sequences and to constructs, vectors, and fungal host cells comprising the signal peptide sequences operably linked to nucleotide sequences encoding polypeptides..
01/09/14
20140011235
Release factor 1 (rf1) in escherichia coli
Provided herein are release factor 1 (rf1) deficient bacteria, methods of using the bacteria to reassign the uag codon, and generate mutant polypeptides.. .


Popular terms: [SEARCH]

Codon topics: Hydrocodone, Nucleic Acid, Acetaminophen, Carboxylic Acid, Benzoic Acid, Genetically, Recombinant, Amino Acid, Nucleotide, Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitor, Reverse Transcriptase, Antibodies, Base Sequence, Replication

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2993

3088

2 - 1 - 72